SANOVO Phase 3 Clinical Study (NCT05009836) is evaluating the efficacy and safety of the combination therapy of savolitinib and osimertinib in patients with EGFR mutation-positive NSCLC and MET overexpression who have not received prior treatment. Here, MET is linked to non-small cell lung carcinoma.